- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05371652
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
An Interventional, Phase 3, Sigle Arm, Open Label Study to Investigate Long-term Safety of Rimegepant Orally Disintegrate Tablets for the Acute Treatment of Migraine in Chinese Participants.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100044
- Peking University People's Hospital
-
Guangzhou, China, 510180
- Guangzhou First People's Hospital
-
-
Anhui
-
Hefei, Anhui, China, 230601
- The Second Hospital of Anhui Medical University
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Beijing Friendship Hospital, Capital Medical University
-
Beijing, Beijing, China, 100089
- Chinese PLA General Hospital
-
-
Chongqing
-
Chongqing, Chongqing, China, 400016
- The First Affiliated Hospital of Chongqing Medical University
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Guangzhou First People's Hospital
-
-
Hainan
-
Haikou, Hainan, China, 570311
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050051
- Hebei General Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Renmin Hospital of Wuhan University
-
Wuhan, Hubei, China, 430074
- Wuhan Third Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410013
- The Third Xiangya Hospital of Central South University
-
Changsha, Hunan, China, 410000
- Changsha Central Hospital
-
Changsha, Hunan, China, 410000
- Xiangya Hospital Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210011
- The Second Affiliated Hospital of Nanjing Medical University
-
-
Jilin
-
Changchun, Jilin, China, 130041
- The Second Hospital of Jilin University
-
Changchun, Jilin, China, 130000
- The Second Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, China, 110801
- General Hospital of Northern Theater Command
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710068
- Shaanxi Provincial People' Hospital
-
Xi'an, Shaanxi, China, 710082
- The First Affiliated Hospital of Xi'an Medical University
-
Xianyang, Shaanxi, China, 712000
- Yan'an University Xianyang Hospital Co., Ltd
-
-
Shandong
-
Liaocheng, Shandong, China, 252000
- LiaoCheng People's Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200065
- Tongji Hospital of Tongji University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- West China Hospital of Sichuan University
-
-
Xinjiang
-
Urumqi, Xinjiang, China, 8320000
- The Second Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, China, 650000
- The Second Affiliated hospital of Kunming Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
At least a one-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition beta version, including the following:
- Age of onset of migraines prior to 50 years of age
- Migraine attacks, on average, lasting 4 - 72 hours if untreated
- 6-18 migraine attacks of moderate or severe intensity per month within the last 3 months prior to the Screening Visit
- 6 or more migraine days requiring treatment during Observation Phase
- Ability to distinguish migraine attacks from tension/cluster headaches
- Subjects on prophylactic migraine medication are permitted to remain on therapy if the dose has been stable dose for at least 2 months prior to the Baseline Visit, and the dose is not expected to change during the course of the study. subjects who previously discontinued prophylactic migraine medication must have done so at least 5 half-lives of the prophylactic medication prior to the Screening Visit
- Subjects with contraindications for use of triptans may be included provided they meet all other study entry criteria
Age and Reproductive Status:
- Male or female subjects ≥ 18 years
- Women of childbearing potential (WOCBP) must voluntarily use 1 acceptable methods of contraception to avoid pregnancy and to minimize the risk of pregnancy from signing of informed consent through 28 days after study drug administration. WOCBP is defined in Section 12.3. No contraception methods are required for male subjects in this study.
Exclusion Criteria:
Target Disease Exclusion:
* Subjects has a history of basilar migraine with brain stem aura or hemiplegic migraine
Medical History and Comorbidities:
- History of HIV disease
- Current evidence of poorly controlled, unstable, or recently diagnosed cardiovascular or cerebrovascular disease such as ischemic heart disease, coronary vasospasm, and cerebral ischemia. Myocardial infarction (MI), acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), cardiac surgery, stroke, or transient ischemic attack (TIA) during 6 months prior to screening
- Poorly controlled hypertension (high blood pressure) or poorly controlled diabetes (but subjects with stable hypertension and/or diabetes for at least 3 months prior to screening may be included in the study). Blood pressure greater than 150 mmHg systolic or 100 mmHg diastolic after 10 minutes of rest is exclusionary
- Subjects with a current diagnosis of major depression or a major depressive episode within the last 12 months, other pain syndromes, psychiatric disorders, dementia, or significant neurological disorders (other than migraine) that, in the opinion of the investigator, might interfere with study assessments
- History of gastric or small intestinal surgery (including gastric bypass, gastric banding, gastric sleeve, gastric water ball, etc.) or diseases resulting in malabsorption
- Subject has a history or diagnosis of Gilibert's Syndrome or any other active hepatic or biliary disorder
- History or presence of significant and/or unstable medical conditions (e.g., history of congenital heart disease or cardiac arrhythmia, known suspected infection, hepatitis B or C or neoplasm) that, in the opinion of the investigator, would expose the subjects to undue risk of a significant adverse events (AE) or interfere with the assessment of safety or effectiveness during the trial
- History or evidence of alcohol or drug abuse within the past 12 months, or treatment for alcohol or drug abuse, or meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for any significant substance abuse disorder within the past 12 months prior to the Screening Visit
- Subjects should be excluded if they have a positive drug screen for drugs of abuse and are considered medically significant by the investigator, would compromise subject safety, or interfere with the interpretation of study results. In addition:
- Subjects with detectable levels of cocaine, amphetamines, and phencyclidine in drug abuse screening need to be excluded.
Subjects who are positive for amphetamines on the urine drug screen may have their urine samples evaluated for further analysis at the investigator's discretion to rule out a false positive result
- Subjects with detectable levels of marijuana during substance abuse screening may not be excluded if they do not meet DSMV criteria for substance abuse or dependence in the subject's opinion as documented by the investigator, and a positive result does not signal a clinical condition that would impact the subject safety or interpretation of the study results
- Diagnosis of hematologic or solid malignancy within 5 years prior to screening. Subjects with a history of localized basal cell or squamous cell skin cancer may be included in the study if they are cancer-free prior to the screening visit for this study
- Subjects with a current diagnosis of schizophrenia, major depression requiring treatment with atypical antipsychotics, bipolar disorder or borderline personality disorder
- Body mass index (BMI) ≥ 35 kg/ m2
- Subjects with a history of gallstones or cholecystectomy
- Use of St. John's Wort, products containing St. John's Wort, Coltsfoot root, or extracts within 14 days prior to the baseline visit
- Use of narcotic drugs such as opioids (e.g., morphine, codeine, oxycodone, and hydrocodone) within 2 days prior to the baseline visit.
Allergy and Adverse Reactions:
*. History of drug or other allergy that, in the opinion of the investigator, would make the subject unsuitable for participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rimegepant 75mg Orally Disintegrating Tablets (ODT)
One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day)
|
One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the long-term safety and tolerability of 75 mg rimegepant ODT (PRN)
Time Frame: Through study completion, 52 weeks
|
Adverse events, common adverse events (incidence ≥5%), serious adverse events, adverse events leading to study drug discontinuation, etc.; ECG, vital signs/physical measurements and clinical laboratory test abnormalities.
|
Through study completion, 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the number of migraine days and severity of migraine attacks during long-term treatment with 75 mg rimegepant ODT (PRN) in participants compared to the Observation Period.
Time Frame: Through study completion, 52 weeks
|
Change from Observation Period in the number of migraine days by total and moderate or severe pain intensity for every 4-week interval and overall period during long-term treatment with 75 mg rimegepant ODT.
|
Through study completion, 52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BHV3000-318
- C4951018 (Other Identifier: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Migraine
-
Behar, Caren, M.D.UnknownMigraine | Migraine Disorders | Migraine Headache | Acute MigraineUnited States
-
PfizerCompletedAcute MigraineUnited States
-
Neurolief Ltd.CompletedAcute MigraineUnited States, Israel
-
IlDong Pharmaceutical Co LtdCompletedAcute MigraineKorea, Republic of
-
Chordate MedicalTerminated
-
Chordate MedicalTerminated
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Lateral Pharma Pty LtdCompletedAcute MigraineAustralia
-
Eli Lilly and CompanyCoLucid PharmaceuticalsCompletedAcute MigraineUnited States
Clinical Trials on Rimegepant 75mg Orally Disintegrating Tablets (ODT)
-
Flex Pharma, Inc.TerminatedCharcot-Marie-Tooth DiseaseUnited States
-
Flex Pharma, Inc.TerminatedMotor Neuron DiseaseUnited States
-
First Affiliated Hospital of Zhejiang UniversityShenyang Sunshine Pharmaceutical Co., LTD.UnknownImprovement of Pruritus in Hemodialysis PatientsChina
-
Eli Lilly and CompanyCompleted
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Eli Lilly and CompanyCompletedSickle Cell DiseaseUnited States
-
University Hospital, LilleInnovative Medicines InitiativeCompletedAlzheimer Disease | BatteryFrance
-
Actavis Inc.Completed
-
Actavis Inc.CompletedHealthyUnited States
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States